CORPORATES HEALTH Indoco Remedies receives USFDA final approval for Brivaracetam Oral Solution 10 mg/mL Feb 24, 2026
QUARTERLY RESULTS Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore Feb 3, 2026
CORPORATES Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations Sep 19, 2025
Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore Jan 21, 2025
Indoco Remedies shares down nearly 2% after USFDA classifies Goa facility as ‘Official Action Indicated’ Oct 14, 2024
Indoco Remedies shares surge 3% after company gets USFDA approval for Generic Cetirizine Hydrochloride tablets Oct 4, 2024